Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Alpine Immune Sciences, Inc. ALPN NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
31/100
0/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$55.00
-15.3%

Alpine Immune Sciences, Inc. (ALPN) is a Biotechnology company in the Healthcare sector, currently trading at $64.97. It has a SharesGrow Score of 31/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is ALPN = $55 (-15.3% upside).

Financials: revenue is $59M, +91.7%/yr average growth. Net income is $32M (loss), growing at -16.9%/yr. Net profit margin is -54.7% (negative). Gross margin is -37.4% (+153.8 pp trend).

Balance sheet: total debt is $10M against $328M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 7.86 (strong liquidity). Debt-to-assets is 2.6%. Total assets: $380M.

Analyst outlook: 9 / 15 analysts rate ALPN as buy (60%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 20/100 (Fail), Growth 58/100 (Partial), Past 0/100 (Fail), Health 67/100 (Partial), Moat 27/100 (Fail), Future 37/100 (Fail), Income 10/100 (Fail).

$55.00
▼ 15.35% Downside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for Alpine Immune Sciences, Inc., the average price target is $55.00, with a high forecast of $65.00, and a low forecast of $44.00.
Highest Price Target
$65.00
Average Price Target
$55.00
Lowest Price Target
$44.00

ALPN SharesGrow Score Overview

37/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 20/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 27/100
Gross margin is + market cap
FUTURE 37/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ALPN

✗
VALUE Fail
20/100
ALPN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $55, implying -15.3% from the current price $65. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ALPN: +91.7%/yr revenue is, -16.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet ALPN: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 7.86 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
27/100
ALPN: Gross margin is -37.4% (+153.8 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 27/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
37/100
Analyst outlook: 9 / 15 analysts rate ALPN as buy (60%). Analyst consensus target is $55 (-15.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ALPN: Net profit margin is -54.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range8.33-65.0
Volume4.29M
Avg Volume (30D)2.37M
Market Cap$4.46B
Beta (1Y)0.97
Share Statistics
EPS (TTM)-0.64
Shares Outstanding$50M
IPO Date2015-06-17
Employees142
CEOMitchell H. Gold
Financial Highlights & Ratios
Revenue (TTM)$58.88M
Gross Profit$-22.03M
EBITDA$-43.67M
Net Income$-32.18M
Operating Income$-44.25M
Total Cash$327.41M
Total Debt$9.91M
Net Debt$-34.01M
Total Assets$379.85M
Price / Earnings (P/E)-101.5
Price / Sales (P/S)75.7
Analyst Forecast
1Y Price Target$55.00
Target High$65.00
Target Low$44.00
Upside-15.3%
Rating ConsensusBuy
Analysts Covering15
Buy 60% Hold 40% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS02083G1004

Price Chart

Track all markets on TradingView
ALPN
Alpine Immune Sciences, Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
8.33 52WK RANGE 65.00

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 MLTX
MLTX
MoonLake Immunotherapeutics
$18.78
+1.90%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message